• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体外研究 12 种抗生素单独及联合应用对 27 株源自意大利感染性心内膜炎患者粪肠球菌的活性作用:头孢曲松-磷霉素联合具有高度体外协同作用。

In vitro activity effects of twelve antibiotics alone and in association against twenty-seven Enterococcus faecalis strains isolated from Italian patients with infective endocarditis: high in vitro synergistic effect of the association ceftriaxone-fosfomycin.

机构信息

UOC Microbiologia e Virologia, AO Ospedale San Carlo Borromeo, Milano, Italia.

出版信息

Chemotherapy. 2011;57(5):426-33. doi: 10.1159/000330458. Epub 2011 Nov 26.

DOI:10.1159/000330458
PMID:22122863
Abstract

BACKGROUND

In 2004-2008, the epidemiological and clinical Infective Endocarditis Study Group (SEI) evaluated 852 cases of infective endocarditis. Staphylococcus aureus was the main involved pathogen (24.5%) and Enterococcus faecalis etiology was described in 11% of the cases. The aim of this study was to evaluate the in vitro activity of 12 antibiotics alone and in association against 27 strains of E. faecalis isolated from blood cultures of patients with infective endocarditis.

RESULTS

The results showed high in vitro activity of tigecycline, daptomycin and linezolid. A high synergistic effect was obtained with the association ceftriaxone-fosfomycin [fractional inhibitory concentration (FIC)(50) = 0.34, FIC(90) = 0.78]. Furthermore, ceftriaxone plus ampicillin presented additive results (FIC(50) = 0.66, FIC(90) = 1.00), and ceftriaxone plus fosfomycin and ceftriaxone plus ampicillin were significantly more active in vitro than each drug alone. The efficacy of ceftriaxone plus fosfomycin was confirmed by the association testing using the broth dilution technique.

CONCLUSION

Fosfomycin seems particularly significant and its association with ceftriaxone could be considered as a useful therapeutic option in medical treatment of E. faecalis infective endocarditis.

摘要

背景

2004-2008 年,感染性心内膜炎研究组(SEI)评估了 852 例感染性心内膜炎患者。金黄色葡萄球菌是主要的病原体(24.5%),11%的病例由粪肠球菌引起。本研究的目的是评估 12 种抗生素单独和联合治疗 27 株粪肠球菌的体外活性,这些菌株均从感染性心内膜炎患者的血培养中分离得到。

结果

研究结果表明,替加环素、达托霉素和利奈唑胺具有较高的体外活性。头孢曲松-磷霉素联合使用具有高度协同作用[半数抑制浓度(FIC)(50)=0.34,FIC(90)=0.78]。此外,头孢曲松联合氨苄西林具有相加作用(FIC(50)=0.66,FIC(90)=1.00),头孢曲松联合磷霉素和头孢曲松联合氨苄西林的体外活性均明显优于单独使用每种药物。联合肉汤稀释技术的药敏试验证实了头孢曲松联合磷霉素的疗效。

结论

磷霉素具有显著的作用,其与头孢曲松的联合应用可能是治疗粪肠球菌感染性心内膜炎的一种有效治疗选择。

相似文献

1
In vitro activity effects of twelve antibiotics alone and in association against twenty-seven Enterococcus faecalis strains isolated from Italian patients with infective endocarditis: high in vitro synergistic effect of the association ceftriaxone-fosfomycin.体外研究 12 种抗生素单独及联合应用对 27 株源自意大利感染性心内膜炎患者粪肠球菌的活性作用:头孢曲松-磷霉素联合具有高度体外协同作用。
Chemotherapy. 2011;57(5):426-33. doi: 10.1159/000330458. Epub 2011 Nov 26.
2
In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates.基于磷霉素的联合用药在体外对临床耐万古霉素肠球菌分离株的疗效。
Diagn Microbiol Infect Dis. 2013 Nov;77(3):254-7. doi: 10.1016/j.diagmicrobio.2013.07.012. Epub 2013 Sep 9.
3
Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis.在高水平氨基糖苷类耐药粪肠球菌中,达托霉素不敏感性的早期体外发展可预测在实验性心内膜炎体内模型中高剂量达托霉素加氨苄西林联合用药的疗效。
J Antimicrob Chemother. 2017 Jun 1;72(6):1714-1722. doi: 10.1093/jac/dkx016.
4
Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides.氨苄西林联合头孢曲松和庆大霉素治疗对氨基糖苷类无高水平耐药的粪肠球菌所致实验性心内膜炎的疗效
J Antimicrob Chemother. 2003 Sep;52(3):514-7. doi: 10.1093/jac/dkg360. Epub 2003 Aug 13.
5
Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis.氨苄西林联合头孢曲松治疗粪肠球菌感染性心内膜炎的疗效与氨苄西林联合庆大霉素相当。
Clin Infect Dis. 2013 May;56(9):1261-8. doi: 10.1093/cid/cit052. Epub 2013 Feb 7.
6
Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis.粪肠球菌感染性心内膜炎的门诊胃肠外抗菌治疗
J Clin Pharm Ther. 2018 Apr;43(2):220-223. doi: 10.1111/jcpt.12635. Epub 2017 Oct 13.
7
Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.在体外药代动力学/药效学模拟心内膜赘生物模型中评估达托霉素联合头孢曲松对耐万古霉素肠球菌的新组合疗效。
J Antimicrob Chemother. 2014 Aug;69(8):2148-54. doi: 10.1093/jac/dku113. Epub 2014 Apr 28.
8
Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations.头孢洛林联合氨苄西林在模拟心内膜赘生物药代动力学/药效学模型中对粪肠球菌的药效学研究
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02235-16. Print 2017 Apr.
9
Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone.过去 15 年西班牙粪肠球菌感染性心内膜炎治疗的变化:从氨苄西林联合庆大霉素到氨苄西林联合头孢曲松。
Clin Microbiol Infect. 2014 Dec;20(12):O1075-83. doi: 10.1111/1469-0691.12756. Epub 2014 Aug 11.
10
Success of ampicillin plus ceftriaxone rescue therapy for a relapse of Enterococcus faecalis native-valve endocarditis and in vitro data on double beta-lactam activity.氨苄西林联合头孢曲松挽救治疗粪肠球菌自体瓣膜心内膜炎复发的成功案例及双β-内酰胺活性的体外数据
Scand J Infect Dis. 2008;40(11-12):968-72. doi: 10.1080/00365540802398945.

引用本文的文献

1
Combination Antibiotic Therapy for Orthopedic Infections.用于骨科感染的联合抗生素治疗
Antibiotics (Basel). 2025 Jul 29;14(8):761. doi: 10.3390/antibiotics14080761.
2
From Isolation to Application: Utilising Phage-Antibiotic Synergy in Murine Bacteremia Model to Combat Multidrug-Resistant Enterococcus faecalis.从分离到应用:在小鼠菌血症模型中利用噬菌体 - 抗生素协同作用对抗耐多药粪肠球菌
Microb Biotechnol. 2025 Jan;18(1):e70075. doi: 10.1111/1751-7915.70075.
3
The Impact of Fosfomycin on Gram Negative Infections: A Comprehensive Review.
磷霉素对革兰氏阴性菌感染的影响:一项全面综述。
Indian J Microbiol. 2024 Sep;64(3):846-858. doi: 10.1007/s12088-024-01293-8. Epub 2024 May 7.
4
New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.感染性心内膜炎的新型抗菌药物及新治疗策略:需加以捍卫的武器
J Clin Med. 2023 Dec 14;12(24):7693. doi: 10.3390/jcm12247693.
5
Treatment of Infective Endocarditis: A Continuing Challenge.感染性心内膜炎的治疗:一项持续的挑战。
Antibiotics (Basel). 2023 Apr 4;12(4):704. doi: 10.3390/antibiotics12040704.
6
Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies.磷霉素作为全身感染管理的联合用药。对其体外和体内研究协同特性的系统评价。
Antibiotics (Basel). 2020 Aug 10;9(8):500. doi: 10.3390/antibiotics9080500.
7
New evidence on the use of fosfomycin for bacteremia and infectious endocarditis.磷霉素用于治疗菌血症和感染性心内膜炎的新证据。
Rev Esp Quimioter. 2019 May;32 Suppl 1(Suppl 1):25-29.
8
A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.肠球菌属血流感染和感染性心内膜炎的联合抗菌治疗综述
Clin Infect Dis. 2018 Jul 2;67(2):303-309. doi: 10.1093/cid/ciy064.
9
Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.联合抗生素疗法治疗肠球菌性感染性心内膜炎。
Infection. 2016 Jun;44(3):273-81. doi: 10.1007/s15010-015-0836-0. Epub 2015 Sep 1.
10
Mechanisms of antibiotic resistance in enterococci.肠球菌的抗生素耐药机制。
Expert Rev Anti Infect Ther. 2014 Oct;12(10):1221-36. doi: 10.1586/14787210.2014.956092.